Tina Moller Tagmose, Novo Nordisk A/S, Denmark
Millions of people with diabetes suffer from the burden of daily subcutaneous insulin injections. Engineering a basal insulin for once weekly injection will result in fewer injections and likely improved acceptance of and compliance to the treatment, thereby improving glucose con [....] » Read More